
    
      PRIMARY OBJECTIVES:

      I. To evaluate the efficacy and safety of denosumab therapy for the treatment of bone loss in
      patients who have received an allogeneic hematopoietic stem cell transplant.

      OUTLINE:

      Patients receive 2 doses of denosumab subcutaneously (SC) between days 70-130 and days
      250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment patients are followed up at 6 months.
    
  